Aaron B. Cowley (Ph.D. in chemistry/MBA) is the Chief Scientific Officer at ReciBioPharm, formerly known as Arranta Bio (2019-Present; the biologics division of ReciPharm, a top-7 CDMO globally with nearly +5200 employees). ReciBioPharm is a leading CDMO focused on Advanced Therapy Medicinal Products (ATMP), including but not limited to Live Biotherapeutic Products (LBPs), xRNA, Viral Vectors, Enzymes and pDNA.  Prior to joining Arranta Bio, Aaron was the co-founder and the Chief Technical Officer of Captozyme (2009-2019; Gainesville, FL), an emerging biotechnology and service-based company that was acquired by Arranta Bio in 2019. Aaron was also a founding member and Board Member of a small biotechnology company, Oxidien Pharmaceuticals, developing therapeutic enzymes that was acquired in 2023.  Aaron is a Chemist, with a focus on redox potentiometry and its impact on the function of enzymes both in vitro and in vivo.  His work has resulted in numerous publications, patents, grant funds and private/venture capital funding. He spearheads the vision and execution of the continuous manufacturing platform being developed for xRNA at ReciBioPharm as part of the funding awarded by the FDA to MIT. Lastly, Aaron is one of the founders and participating members of the MIT Center of Continuous mRNA Manufacturing.